
GNFT Stock Forecast & Price Target
GNFT Analyst Ratings
Bulls say
Genfit SA has established a positive outlook driven by its strategic partnership with Ipsen, which reported €59 million in sales of Iqirvo for primary biliary cholangitis (PBC) and expects growth to accelerate in the U.S. Furthermore, Ipsen's positive Phase 2 data in primary sclerosing cholangitis (PSC) presents additional opportunities for milestone achievements, enhancing investor confidence. Lastly, Genfit's diversified pipeline, combined with its strategic alliances and proven execution history, reduces binary risk and supports a favorable assessment of its overall financial health.
Bears say
Genfit SA faces significant challenges that contribute to a negative outlook on its stock, primarily due to clinical and regulatory uncertainties surrounding its pipeline assets. The company's decision to halt the development of VS-01 for ACLF patients, prompted by serious adverse events, underscores the risks associated with its research endeavors. Additionally, the potential need for further financing to sustain pipeline expansion amidst competitive dynamics in the liver disease sector adds to the financial instability concerns facing the company.
This aggregate rating is based on analysts' research of Genfit - ADR and is not a guaranteed prediction by Public.com or investment advice.
GNFT Analyst Forecast & Price Prediction
Start investing in GNFT
Order type
Buy in
Order amount
Est. shares
0 shares